2015
DOI: 10.4172/2376-0427.1000228
|View full text |Cite
|
Sign up to set email alerts
|

Tranexamic Acid in Melasma: A Review

Abstract: Melasma is a localized, chronic acquired hypermelanosis of the skin. Despite several treatments available, melasma can often be refractory to treatment. Also recurrences are common. Tranexamic acid is a new addition in treatment of melasma and is effective in dosage of 250 mg BD for atleast 4 to 8 weeks. Tranexamic acid acts mainly via the plasminogen activator-plasmin system to prevent UV radiation induced pigmentation in melasma. This article reviews the mechanism of action of tranexamic acid in melasma and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
51
0
15

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(66 citation statements)
references
References 20 publications
(20 reference statements)
0
51
0
15
Order By: Relevance
“…Topical TA is postulated to inhibit plasminogen from binding to keratinocytes by various mechanisms. It is thought to interfere with the lysin binding sites on keratinocytes which in turn downregulates prostaglandin, a stimulator of tyrosinase, resulting in a decline in tyrosinase activity and melanogenesis (Li, Shi, Li, Liu, & Feng, 2010;Poojary & Minni, 2015). TA is also found to block the Sc-uPA pathway and affect the plasminogen plasmin system, which eventually reduces hyperpigmentation (Maeda & Tomita, 2007).…”
Section: Resultsmentioning
confidence: 99%
“…Topical TA is postulated to inhibit plasminogen from binding to keratinocytes by various mechanisms. It is thought to interfere with the lysin binding sites on keratinocytes which in turn downregulates prostaglandin, a stimulator of tyrosinase, resulting in a decline in tyrosinase activity and melanogenesis (Li, Shi, Li, Liu, & Feng, 2010;Poojary & Minni, 2015). TA is also found to block the Sc-uPA pathway and affect the plasminogen plasmin system, which eventually reduces hyperpigmentation (Maeda & Tomita, 2007).…”
Section: Resultsmentioning
confidence: 99%
“…Melasma predominantly is clinically characterized by blotchy hyper pigmentation of the face particularly the forehead and malar eminences and to a lesser degree lower portion of the cheeks, chin, the upper lip and the sides of the neck. 6 Treatment of melasma using tranexamic acid is a novel concept. 7 Nijor in Japan first studied and reported action of tranexamic acid on melasma in 1979.…”
Section: Discussionmentioning
confidence: 99%
“…Indikasi umum penggunaan AT adalah untuk pencegahan dan pengobatan perdarahan, 12 akan tetapi, AT juga digunakan sebagai agen pencerah kulit dalam bidang kosmetik. 13,14 Efek AT sebagai pencerah kulit pertama kali ditemukan oleh Nijo di Jepang pada tahun 1979, saat digunakan pada pasien dengan urtikaria kronik. 15 Pemberian AT oral dengan dosis 750 mg/kgBB juga telah terbukti dapat mengurangi keriput akibat kulit kering, menurunkan kadar MMP-1, meningkatkan kandungan kolagen, menurunkan proliferasi sel mast, dan meningkatkan proliferasi sel fibroblas pada mencit hairless tipe Naruto Research Institute Otsuka Atrichia (NOA).…”
Section: Pendahuluanunclassified
“…Hal ini sejalan dengan berbagai penelitian sebelumnya yang telah menggunakan krim AT dengan konsentrasi 2% hingga 5% untuk mengobati melasma dengan mekanisme kerja yang sama. 14,21,22 Pada penelitian ini, krim AT diberikan segera setelah pajanan sinar UVB. Hal ini sejalan dengan metode penelitian yang dilakukan oleh Li et al yang memberikan larutan AT 3% secara intradermal segera dilakukan pajanan sinar UVB.…”
Section: Kelompok Perlakuan Skor Keriput Kadar Mmp-1unclassified